1. Home
  2. FTS vs NTRA Comparison

FTS vs NTRA Comparison

Compare FTS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortis Inc.

FTS

Fortis Inc.

HOLD

Current Price

$51.19

Market Cap

26.0B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTS
NTRA
Founded
1885
2003
Country
Canada
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FTS
NTRA
Price
$51.19
$244.06
Analyst Decision
Hold
Strong Buy
Analyst Count
1
16
Target Price
$72.00
$227.69
AVG Volume (30 Days)
756.4K
1.7M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
3.47%
N/A
EPS Growth
4.08
N/A
EPS
2.41
N/A
Revenue
$8,643,898,655.00
$2,116,676,000.00
Revenue This Year
$13.04
$32.77
Revenue Next Year
$4.82
$16.51
P/E Ratio
$21.10
N/A
Revenue Growth
5.21
38.17
52 Week Low
$40.32
$125.38
52 Week High
$52.83
$245.59

Technical Indicators

Market Signals
Indicator
FTS
NTRA
Relative Strength Index (RSI) 45.70 80.03
Support Level $51.10 $233.67
Resistance Level $52.56 $240.18
Average True Range (ATR) 0.63 7.39
MACD -0.14 0.68
Stochastic Oscillator 18.47 97.49

Price Performance

Historical Comparison
FTS
NTRA

About FTS Fortis Inc.

Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: